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Abstract Time kinetics of phosphatidyl serine (PS) exposure
were compared to other apoptotic parameters following different
apoptotic stimuli. Our data indicate that anti-Fas treatment of
L929sAhFas cells results in rapid exposure of PS, which precedes
decrease in mitochondrial transmembrane potential (v8m) and
release of cytochrome c, indicating that PS exposure occurs
independently of these mitochondrial events. Also during TNF-,
etoposide- or staurosporine-mediated apoptosis in PC60 RI/RII
cells, PS-positive cells were observed before they had a decreased
v8m. However, during growth factor depletion-induced death of
32D cells, both phenomena seemed to occur at the same time.
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1. Introduction
Apoptosis is a multistep process characterized by several
morphological and biochemical alterations [1]. Following
apoptotic trigger, a chain of events leads to cell shrinkage,
membrane blebbing, nuclear condensation, loss of membrane
integrity and enzymatic DNA degradation. It is well estab-
lished now that caspase-dependent proteolysis is crucial in
the apoptotic process [2]. Activation of caspases is initiated
by receptor-mediated oligomerization of procaspases [3] and/
or by release of mitochondrial caspase-activating factors [4^6].
The mitochondrial release of proapoptotic factors is regulated
by members of the Bcl-2 protein family [6,7].
Another important hallmark of the apoptotic process is loss
of aminophospholipid asymmetry of the plasma membrane
[8]. Phosphatidyl serine (PS), which is con¢ned to the inner
membrane lea£et in normal healthy cells, becomes exposed at
the outer plasma membrane of apoptotic cells. Exposure of PS
is an early event, as it precedes cell membrane permeabiliza-
tion, cell shrinkage and nuclear condensation [9]. PS exposure
has been implicated in the recognition of apoptotic cells by
phagocytes and results in rapid engulfment of the apoptotic
cell [10]. Furthermore, PS at the outside of platelets promotes
the assembly of the blood coagulation system [11]. The amino-
phospholipid asymmetry of PS in viable cells results from an
active inward transport of PS by aminophospholipid translo-
case [12,13] and bidirectional transport of phospholipids (PLs)
by scramblase [11,14]. Exposure of PS during apoptosis is
associated with a loss of aminophospholipid translocase activ-
ity and with a non-speci¢c £ip-£op of PLs [15,16].
Besides exposure of PS, also disruption of the mitochon-
drial transmembrane potential (v8m) has been reported to be
an early event in the apoptotic process [1]. v8m results from
an asymmetric distribution of protons on either side of the
inner mitochondrial membrane and is the driving force for
oxidative phosphorylation. Collapse of v8m during apoptosis
has been observed in many di¡erent cell types, irrespective of
the apoptotic stimulus. The mitochondrial intermembrane
fraction contains several proapoptotic proteins released dur-
ing the apoptotic process, such as cytochrome c [4], procas-
pase-2, -3 and -9 [17,18], as well as apoptosis-inducing factor
(AIF) [19]. The latter, recently identi¢ed as a £avoprotein with
homology to bacterial oxido-reductases, can cause chromatin
condensation in isolated nuclei as well as release of cyto-
chrome c and caspase-9 from puri¢ed mitochondria. When
overexpressed, AIF also induces collapse of v8m, exposure
of PS and hypoploidy [6,19]. The functional correlation be-
tween decrease in v8m and release of these proapoptotic fac-
tors is not clear. In this respect, it has been reported that
release of cytochrome c can occur without loss of v8m [20].
It has been reported that during dexamethasone-induced
apoptosis in splenocytes or thymocytes, cells ¢rst exhibit a
decreased v8m followed by PS exposure [21,22]. Other reports
mention that PS exposure only slightly precedes or coincides
with collapse of v8m in 1-L-D-arabinofuranosylcytosine-in-
duced apoptosis in leukemic blast cells, in anti-Fas-induced
apoptosis in Jurkat cells and in etoposide- or N-tosyl-L-phe-
nylalanine chloromethylketone-elicited apoptosis in THP-1
cells [23^25]. Therefore, we examined the time course of these
two early apoptotic phenomena, viz. exposure of PS and de-
crease in v8m in di¡erent cell lines after various apoptotic
stimuli. Time kinetic studies were performed on anti-Fas-
treated L929sAhFas cells, on TNF-, staurosporine (STS)-
and etoposide-stimulated PC60 RI/RII cells and on growth
factor-depleted 32D cells.
2. Materials and methods
2.1. Cell cultures
L929sAhFas is a murine ¢brosarcoma cell line transfected with the
human Fas (hFas) receptor [26]. hFas cDNA was kindly provided by
Dr. S. Nagata (Osaka Bioscience Institute, Osaka, Japan). Cells were
grown in DMEM medium, supplemented with 5% fetal calf serum,
5% newborn calf serum, penicillin (100 U/ml), streptomycin sulfate
(100 Wg/ml) and L-glutamine (2 mM). Hybridoma PC60.21.14.4
(PC60), derived from a fusion between an IL-2-dependent murine
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CTL line B6.1SF.1 and a rat thymoma (C58.NT)D [27], was kindly
provided by Dr. M. Nabholz (Swiss Institute for Experimental Cancer
Research, EŁ palinges, Switzerland). Transfection of these cells with
TNF-RI and TNF-RII was described previously [28]. Cells were
grown in RPMI 1640 medium, supplemented with 10% fetal calf se-
rum, penicillin (100 U/ml), streptomycin sulfate (100 Wg/ml), L-gluta-
mine (2 mM), sodium pyruvate (1 mM) and L-mercaptoethanol
(2U1035 M). The IL-3-dependent murine myeloid leukemic cell line
32D was maintained in RPMI 1640 medium, supplemented with 10%
fetal calf serum, 10% WEHI-3B cell-conditioned medium as a source
of murine IL-3, penicillin (100 U/ml), streptomycin sulfate (100 Wg/
ml), L-glutamine (2 mM), sodium pyruvate (1 mM) and L-mercapto-
ethanol (2U1035 M).
2.2. Cytokines and reagents
Anti-hFas antibody (clone 2R2) was purchased from Cell Diagnos-
tica (Mu«nster, Germany). Recombinant human TNF was produced in
Escherichia coli and puri¢ed in our laboratory. The speci¢c biological
activity of TNF was 9.4U107 IU/mg, based on a standardized cyto-
toxic assay on WEHI 164 cl 13 cells [29]. The TNF standard was
obtained from the National Institute for Biological Standards and
Control (Potters Bar, UK). STS was purchased from Roche Diagnos-
tics (Basel, Switzerland) and was stored as a solution in DMSO.
Carbonyl cyanide m-chlorophenylhydrazone (mClCCP) and etopo-
side were purchased from Sigma Chemical (St. Louis, MO, USA);
the latter was solubilized in ethanol or DMSO. Propidium iodide
(PI; Becton-Dickinson, Sunnyvale, CA, USA) was prepared as a
3 mM stock solution in phosphate-bu¡ered saline and was used at
30 WM. The £uorescent marker chloromethyltetramethylrosamine
(CMTMros) was purchased from Molecular Probes (Eugene, OR,
USA); it was prepared as a 1 mM stock solution in DMSO and
was used at 0.05 WM. Annexin V (FITC conjugate; PharMingen,
San Diego, CA, USA) was used at 1 Wg/ml.
2.3. Induction of apoptosis
L929sAhFas cells for FACS analysis were kept in suspension by
seeding 2U105 cells the day before in uncoated 24 well tissue culture
plates. PC60 RI/RII cells or 32D cells (1U105) were cultured from the
day before in 24 well tissue culture plates, the latter in the presence of
10% WEHI-3B cell-conditioned medium. The next day, anti-Fas
(250 ng/ml) was added to L929sAhFas cells and TNF (100 ng/ml),
STS (2 WM) or etoposide (50 Wg/ml) to PC60 RI/RII cells. 32D cells
were washed three times and resuspended in the presence or absence
of WEHI-3B cell-conditioned medium. Cell samples were taken at
regular time intervals and analyzed on a FACScalibur £ow cytometer
(Becton-Dickinson, Sunnyvale, CA, USA).
2.4. Cyto£uorometric analysis of v8m, cell membrane alterations and
hypoploidy
To measure the decrease in v8m, the £uorogenic probe CMTMros
was used [30]. Cells were incubated at 37‡C for 15 min in the presence
of CMTMros (0.05 WM) and then left on ice for 10 min before anal-
ysis on a FACScalibur £ow cytometer. CMTMros £uorescence was
excited with an argon ion laser (250 mW) at 488 nm and detected
between 545 and 615 nm. Exposure of PS at the cell surface was
analyzed with annexin V [31]. Cells were washed in HEPES bu¡er
(10 mM HEPES NaOH, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM
MgCl2 and 1.8 mM CaCl2) and incubated for 5 min on ice with
annexin V (1 Wg/ml; excitation at 488 nm and detection between
515 and 550 nm). The loss of cell membrane integrity was determined
on all cells by means of a PI exclusion method [28,32]. Each sample
was incubated with 30 WM PI, 3^10 min before analysis on a FACS-
calibur £ow cytometer. The dye was excited with the 488 nm line of
an argon ion laser and £uorescence emission was measured at 610 nm.
The percentage of cells containing hypoploid DNA was determined
on all cells by PI staining of cells after one freeze-thaw cycle to per-
meabilize the cells.
2.5. Cytochrome c release
Cells were treated with anti-Fas (250 ng/ml) and were washed in
cold PBS-A. They were permeabilized with 100 Wl 0.02% digitonin
dissolved in cell-free system bu¡er (220 mM mannitol, 68 mM su-
crose, 2 mM MgCl2, 2 mM NaCl, 2.5 mM H2KPO4, 0.5 mM
EGTA, 0.5 mM sodium pyruvate, 0.5 mM L-glutamine and 10 mM
HEPES NaOH pH 7.4) and were left on ice for 1 min. After centri-
fugation, the supernatant was dissolved in Laemmli bu¡er; it was
analyzed by 15% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and Western blotting using a monoclonal antibody to cyto-
chrome c (PharMingen, San Diego, CA, USA) and ECL-based detec-
tion.
3. Results
3.1. Surface exposure of PS in apoptotic L929sAhFas cells
precedes collapse of v8m, release of cytochrome c, loss of
membrane integrity and appearance of hypoploid DNA
L929sAhFas cells die apoptotically when exposed to anti-
Fas agonistic antibodies, characterized by caspase activation,
extensive membrane blebbing, hypoploid DNA pattern and
nuclear condensation [26]. Simultaneous two-parameter anal-
ysis was performed in order to examine the time sequence of
exposure of PS in relation to the disruption of v8m during
anti-Fas-induced apoptosis in L929sAhFas cells. Both phe-
nomena have been reported to occur at an early stage in the
apoptotic process [33]. To measure the extent of PS exposure,
cells were labeled with annexin V, which speci¢cally binds PS
in a calcium-dependent way. v8m was measured with
CMTMros. The accumulation of CMTMros in the mitochon-
dria depends on active mitochondria with an intact v8m ; this
is an irreversible process, as the chloromethyl group reacts
with intramitochondrial thiols forming a thioester bond. To
con¢rm that CMTMros-based measurements were indeed due
to a decrease in v8m, L929sAhFas cells were pretreated with
100 WM mClCCP, an uncoupling agent of mitochondrial ox-
idative phosphorylation. After 30 min incubation with
mClCCP before staining with CMTMros, the cells shifted to
a weaker £uorescence intensity (data not shown).
Control cells did not bind annexin V-FITC, while anti-Fas-
treated cells displayed rapid staining, which was already de-
tectable after 10 min and which was maximal 60 min after
addition of anti-Fas (Fig. 1A). Although a small portion of
the cells showed an early drop in v8m (v8 lowm /PS-negative
cells, lower left quadrant), the majority of the cells ¢rst be-
came annexin V-positive with a normal v8m (v8 highm /PS-pos-
itive cells, upper right quadrant) before losing v8m (v8 lowm /
PS-positive cells, lower right quadrant) (Fig. 1A). To avoid
misinterpretation of annexin V or CMTMros staining, expo-
sure of PS and loss of v8m were measured on the cell pop-
ulation still sharing the scatter characteristics of viable cells.
Indeed, all cells with the scatter pro¢le of shrunken dead cells
showed enhanced annexin V and diminished CMTMros stain-
ing, as a consequence of permeabilization of their cellular and
mitochondrial membranes, respectively (data not shown).
We also investigated the time kinetics of other apoptotic
parameters, viz. loss of cell membrane integrity (measured
with PI) and appearance of a hypoploid DNA pattern (meas-
ured with PI on permeabilized cells) compared to surface ex-
posure of PS and decrease in v8m. The latter phenomena
occurred clearly before the cells lost their plasma membrane
integrity and started to fragment their nuclear DNA, eventu-
ally leading to a hypoploid DNA content (Fig. 1B).
Finally, we compared the surface exposure of PS and re-
lease of cytochrome c from the mitochondria after anti-Fas
stimulation. Release of cytochrome c in the cytosol was de-
termined by digitonin treatment, which under proper condi-
tions only a¡ects the outer cell membranes and leaves the
membranes of organelles intact. As shown in Fig. 1C, expo-
sure of PS clearly precedes the release of cytochrome c after
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anti-Fas treatment. Apparently, releasable cytochrome c does
not gradually accumulate in the cytosol, but is suddenly, and
almost maximally, released during a short period of time,
namely 40^50 min after addition of anti-Fas. Although the
time of maximal cytochrome c release may vary from experi-
ment to experiment, rapid accumulation of releasable cyto-
chrome c in the cytosol of anti-Fas-stimulated cells is a recur-
rent observation.
3.2. Comparison of surface PS exposure and decrease in
v8m during apoptosis in PC60 RI/RII cells
We investigated whether the sequence of apoptotic events
described above was also valid for other cells and stimuli,
where the apoptotic process is usually less rapid as compared
to anti-Fas-treated L929sAhFas cells, which die within 3 h
[34]. PC60 RI/RII cells die apoptotically when stimulated
with TNF [28]. A time kinetic was performed on TNF-treated
PC60 RI/RII cells, which were labeled simultaneously with
annexin V and CMTMros. Also here, analysis was performed
only on the cell population with scatter characteristics of via-
ble cells. The viable v8 highm /PS-negative cells moved to the
¢nal apoptotic v8 lowm /PS-positive stage through the intermedi-
ate v8 highm /PS-positive stage, since no PS-negative cells were
detectable with lowered v8m (Fig. 2A). The v8 highm /PS-pos-
itive cells represented only a minor population (less than 15%)
of the total cell culture. Most probably, these cells rapidly
proceeded to a stage with a completely altered scatter pro¢le
once v8m had dropped. In a next set of experiments, we
examined whether this sequence of apoptotic events also oc-
curred after induction of apoptosis with STS or etoposide. In
agreement with the results obtained after TNF treatment, we
observed that PC60 RI/RII cells ¢rst externalized PS and then
shifted to the ¢nal PS-positive/v8 lowm stage (Fig. 2B,C). This
indicates that also under these conditions, exposure of PS
occurred before loss of v8m.
3.3. Comparison of surface PS exposure and decrease in v8m
during apoptosis in growth factor-depleted 32D cells
Finally, we investigated the time kinetics of PS exposure
and decrease in v8m during apoptosis induced by growth
factor withdrawal of 32D cells. In contrast to the other apop-
totic systems studied, no cells accumulated in the v8 highm /PS-
Fig. 1. Time kinetics of anti-Fas-induced exposure of PS, decrease in v8m, cytochrome c release, loss of membrane integrity and hypoploid
DNA in apoptotically dying L929sAhFas cells. Cells were incubated at 2U105 cells/ml with hFas (500 ng/ml). (A) Dot plots simultaneously
stained with annexin V and CMTMros at di¡erent time intervals. (B) Time kinetic analysis of exposure of PS (percentage of annexin V-positive
cells ; black bars) and decrease in v8m (percentage of cells with decreased CMTMros staining; horizontally hatched bars), compared to the per-
centage of hypoploid cells (white bars) and loss of membrane integrity (percentage of PI-positive cells ; diagonally hatched bars). (C) Time
course of exposure of PS compared to release of cytochrome c from the mitochondria. Results are representative of three independent experi-
ments.
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positive transition stage. Neither were cells found in the other
transition stage (v8 lowm /PS-negative) (Fig. 3). Hence, cells dy-
ing from growth factor withdrawal become immediately and
simultaneously v8 lowm /PS-positive. These observations might
be explained either by simultaneous occurrence of both apop-
totic phenomena or, more likely, by a process whereby the
cells remain in the v8 highm /PS-positive transition stage for a
short time.
4. Discussion
Anti-Fas and TNF initiate cell death through the extrinsic
apoptotic pathway, using death domain-containing receptors,
adaptors and recruitment of the initiator procaspase-8 [35].
Recently, two di¡erent pathways of anti-Fas-mediated apop-
tosis have been described [36]. In type-I cells, a large amount
of active caspase-8 is generated at the death-inducing signal-
ing complex (DISC), which directly leads to activation of
downstream caspases. In type-II cells, only a small amount
of DISC is formed, resulting in minor caspase-8 activation. In
this type of cells, propagation and ampli¢cation of the apop-
totic signal by mitochondrial factors is required. The apopto-
genic process of the mitochondria in death domain-initiated
signaling is probably induced by caspase-8-mediated cleavage
of Bid, a proapoptotic member of the Bcl-2 family [5]. The C-
terminal part of Bid translocates to the mitochondria, where it
induces release of cytochrome c, a cofactor in Apaf-1-induced
activation of procaspase-9 [5,37]. STS, etoposide and growth
factor depletion initiate cell death through the intrinsic apop-
totic pathway, initiated by formation of the apoptosome com-
plex, integrating Apaf-1, cytochrome c, ATP and the initiator
procaspase-9. Both cell death pathways converge on the pro-
teolytic activation of the short prodomain e¡ector caspases,
such as caspase-3, -6 and -7 [38].
We compared the time kinetics of surface PS exposure to a
decrease in v8m in di¡erent cell lines, namely L929sAhFas,
PC60 RI/RII and 32D. In this way, we were able to compare
both extrinsically induced apoptosis (Fas, TNF-RI and TNF-
RII) and intrinsically induced apoptosis (STS, etoposide and
growth factor depletion). We demonstrated that during anti-
Fas-induced apoptosis in L929sAhFas cells, PS exposure oc-
curs before decrease in v8m and release of cytochrome c from
Fig. 2. Time kinetic analysis of TNF-induced exposure of PS compared to decrease in v8m in apoptotically dying PC60 RI/RII cells. Cells
were cultured in the presence of 100 ng/ml TNF (A), 50 Wg/ml etoposide (B) or 2 WM STS (C). Dot plots are shown from cells that were
stained simultaneously with annexin V and CMTMros at di¡erent time intervals. Results are representative of three independent experiments.
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the mitochondria. Both phenomena occur before cells exhibit
late apoptotic features, such as DNA hypoploidy and loss of
cell membrane integrity. Also in PC60 RI/RII cells exposed to
TNF, STS or etoposide, exposure of PS occurred before a
decrease in v8m. However, under these conditions, there
was only a small accumulation of PS-positive/v8 highm cells.
Most probably, cells proceeded rapidly to the ¢nal apoptotic
stage, once they lost their v8m. It should be noted that the
time lag between induction of surface PS exposure and de-
crease in v8m is similar (1 h) in anti-Fas-treated L929sAhFas
and TNF-stimulated PC60 RI/RII cells, although maximal
induction of apoptosis in the latter cells takes much longer
(16 h vs. 3 h). This suggests that for two cell types with di¡er-
ent apoptotic kinetics, the time required by the processes be-
tween surface PS exposure and decrease in v8m is similar. In
growth factor-depleted 32D cells, there was almost no accu-
mulation in the PS-positive/v8 highm stage. This observation is
in agreement with previous reports on the simultaneous oc-
currence of both apoptotic events during ara-C-induced apop-
tosis in leukemic blast cells [23]. Also during apoptosis in-
duced by anti-Fas in Jurkat T cells, only few cells were
detected in the transition stages between viable v8 highm /PS-
negative cells and ¢nal apoptotic v8 lowm /PS-positive cells
([24] and our own unpublished results).
The mechanism by which PS is exposed on the outer cell
membrane lea£et is still under investigation. Two enzymes
have been proposed to play an important role in this process.
The PL scramblase is a plasma membrane protein which fa-
cilitates the rapid mobilization of PS to the cell surface upon
elevation of internal Ca2 concentration [14]. The extent to
which PS migrates to the plasma membrane outer lea£et is
correlated with the expression level of scramblase [39]. The
ATP-dependent aminophospholipid translocase belongs to
the subfamily of the P-type ATPases and mediates the inward
transport of PS. Down-modulation of this enzyme during
apoptosis has been implicated in exposure of PS at the outer
cell membrane [15]. Both mitochondria and caspases have
been suggested to play a role in the signaling pathway to PS
exposure. First, it has been shown that exposure of PS on the
cell surface is blocked by caspase inhibitors [40]. Also in PC60
RI/RII cells, TNF-induced exposure of PS and decrease in
v8m are inhibited by zVAD-fmk, a broad-spectrum caspase
inhibitor, or by CrmA expression in these cells (W.D. and
G.D., unpublished results). As CrmA is an inhibitor of cas-
pase-8 [41], these observations favor a mechanism whereby at
least one initial step after receptor clustering, viz. activation of
procaspase-8, is shared by the signaling pathways leading to
PS exposure and decrease in v8m. We demonstrated that also
during etoposide- and STS-induced apoptosis PS exposure
preceded a decrease in v8m, similar to the events following
TNF-RI or Fas triggering. Recently, it was shown that ad-
ministration of either etoposide or STS results in the activa-
tion of procaspase-8 [42,43]. Hence, caspase-8 activation may
occur in drug-induced PS exposure. However, as both zVAD-
fmk and CrmA prevent initiation of the apoptotic process, it
is not clear whether caspases are directly implicated. Secondly,
several reports described that exposure of PS occurs after
mitochondrial damage: release of cytochrome c or decrease
in v8m in di¡erent apoptotic systems takes place before ex-
posure of PS [20^22]; both microinjection of AIF and cyto-
chrome c in cells have been reported to induce PS exposure
[19,44]. These results are not necessarily in contradiction with
ours, as it might be that in these systems post-mitochondrial
activation of e¡ector caspases induces activation of caspase-8
at a later stage of the apoptotic process, which in turn can
lead to PS exposure. Furthermore, it is not unlikely that both
signaling pathways, leading to mitochondrial damage and ex-
posure of PS, are independent events. Depending on the cel-
lular system used, PS exposure can be observed before, simul-
taneously or after mitochondrial damage.
Our results indicate that exposure of PS at the cell surface is
an early event, which might have important implications.
First, as the externalization of PS is involved in recognition
of apoptotic cells by phagocyting cells [10], phagocytosis
might already be initiated before other apoptotic features be-
come apparent. This rapid recognition by phagocytes or
neighboring cells, followed by uptake and degradation of
apoptotic cells, might protect the surrounding tissues from
exposure to cells in late apoptotic stages and might also ex-
plain the apparent absence of full apoptotic cells in vivo [8]. It
was also demonstrated that thymocytes, during glucocorti-
coid-induced apoptosis, die without DNA fragmentation
and become TUNEL-positive only after being phagocytosed
by macrophages [45].
Loss of asymmetric distribution of PS and other compo-
nents of the membrane lipid bilayer might initiate another
signal transduction at an early stage and might be part of
the commitment of the cell to death. Since PS is an essential
cofactor in cell membranes for activation of protein kinase C
(PKC) [46], which is recruited to the membrane by interacting
with diacylglycerol, it is possible that decrease in PS in the
inner membrane is accompanied with loss of PKC activity. A
role for PKC in protecting against cell death has been de-
scribed in di¡erent apoptotic systems. This protection has
been associated with the PKC-induced maintenance of Bcl-2
levels [47]. Recently, a PS-speci¢c phospholipase A1 (PS-
Fig. 3. Time kinetic analysis of growth factor depletion-induced ex-
posure of PS compared to decrease in v8m in 32D cells. Cells were
cultured in the presence or absence of WEHI-3B supernatant as a
source of IL-3. Plots are shown from cells that were stained simulta-
neously with annexin V and CMTMros at di¡erent time intervals
after growth factor withdrawal. Results are representative of three
independent experiments.
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PLA1) was cloned, which acts speci¢cally on PS and 1-acyl-2-
lysophosphatidylserine (lyso-PS) to hydrolyze fatty acids at
the sn-1 position of these PLs [48]. It is likely that PS-PLA1
is involved in regulating PS/lyso-PS-dependent reactions;
however, the physiological role of PS-PLA1 is still unknown.
Our results demonstrate that exposure of PS constitutes an
early event in the apoptotic process, which does not require
loss of v8m and release of cytochrome c. This suggests that
phagocytes recognize apoptotic cells before mitochondrial
dysfunction occurs.
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